Carfilzomib

• Research study to comparison the effectivenes of combination of drugs called lenalidomide, carfilzomib, dexamethasone with combination of dr… Ended
  2024-518473-34-00 Phase III 3 countries Polish Myeloma Consortium
• CC-92480-MM-002 A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Prel… Ended
  2023-505219-19-00 Phase I/II 6 countries Celgene Corp.
• A randomized trial that compares Carfilzomib - Lenalidomide - Dexamethasone (KRd) versus Lenalidomide - Dexamethasone (Rd) in new diagnosed … Ended
  2024-513396-41-00 Phase III 1 country Fondazione European Myeloma Network Italy O.N.L.U.S.
• Treatment with carfilzomib, lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smoldering Multi… Ended
  2024-511334-12-00 Phase II 2 countries Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
• Study to evaluate the efficacy of 3 different treatments, followed by maintenance treatment, in older adult patients, between 65 and 80 year… Ended
  2024-516905-22-00 Phase III 1 country Fundacion PETHEMA
• Elotuzumab (E) in Combination with Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) versus KRd prior to and following Autologous Stem Cel… Ended
  2024-515783-31-00 Phase III 2 countries Universitaetsklinikum Wuerzburg AöR
• A Clinical Phase II, multicenter, Open-label study evaluating iNduction, consolidation and maintenance treatment with Isatuximab (SAR650984)… Ended
  2024-511791-32-00 Phase II 1 country University Medical Center Hamburg-Eppendorf
• A Study to Evaluate Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants with Relapsed or … Ended
  2023-503689-21-00 Phase I/II 5 countries F. Hoffmann-La Roche AG
• Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma af… Ended
  2024-510590-14-00 Phase III 1 country University Medical Center Hamburg-Eppendorf
• ISKPD-IFM2018-03-Multicenter Open label Phase 2 study of Isatuximab plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refr… Ended
  2024-516670-29-00 Phase II 1 country Centre Hospitalier Universitaire De Poitiers
• A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects with … Ended
  2023-509848-10-00 Phase III 7 countries Celgene Corp.
• KRd consolidation in myeloma patients with a positive PET-CT after standard first line treatment. A phase II study Ended
  2024-511714-20-00 Phase II 2 countries Oslo University Hospital HF
• Multicenter trial with carfilzomib combined with lenalidomide or cyclophopshamide with or without autologous transplant in newly diagnosed m… Ended
  2024-516630-35-01 Phase II 1 country Universita' Degli Studi Di Torino
• A Phase 3 Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants with Relapsed or Ref… Ended
  2023-509472-42-00 Phase III 14 countries Celgene International II S.a.r.l.

Showing 25–38 of 38 trials